Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

80 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Effects of RGH-237 [N-{4-[4-(3-aminocarbonyl-phenyl)-piperazin-1-yl]-butyl}-4-bromo-benzamide], an orally active, selective dopamine D(3) receptor partial agonist in animal models of cocaine abuse.
Gyertyán I, Kiss B, Gál K, Laszlovszky I, Horváth A, Gémesi LI, Sághy K, Pásztor G, Zájer M, Kapás M, Csongor EA, Domány G, Tihanyi K, Szombathelyi Z. Gyertyán I, et al. J Pharmacol Exp Ther. 2007 Mar;320(3):1268-78. doi: 10.1124/jpet.106.107920. Epub 2006 Dec 14. J Pharmacol Exp Ther. 2007. PMID: 17170312
Novel sulfonamides having dual dopamine D2 and D3 receptor affinity show in vivo antipsychotic efficacy with beneficial cognitive and EPS profile.
Agai-Csongor E, Nógrádi K, Galambos J, Vágó I, Bielik A, Magdó I, Ignácz-Szendrei G, Keseru GM, Greiner I, Laszlovszky I, Schmidt E, Kiss B, Sághy K, Laszy J, Gyertyán I, Zájer-Balázs M, Gémesi L, Domány G. Agai-Csongor E, et al. Among authors: gyertyan i. Bioorg Med Chem Lett. 2007 Oct 1;17(19):5340-4. doi: 10.1016/j.bmcl.2007.08.015. Epub 2007 Aug 15. Bioorg Med Chem Lett. 2007. PMID: 17720494
Subnanomolar dopamine D3 receptor antagonism coupled to moderate D2 affinity results in favourable antipsychotic-like activity in rodent models: II. behavioural characterisation of RG-15.
Gyertyán I, Sághy K, Laszy J, Elekes O, Kedves R, Gémesi LI, Pásztor G, Zájer-Balázs M, Kapás M, Agai Csongor E, Domány G, Kiss B, Szombathelyi Z. Gyertyán I, et al. Naunyn Schmiedebergs Arch Pharmacol. 2008 Nov;378(5):529-39. doi: 10.1007/s00210-008-0311-x. Epub 2008 Jun 12. Naunyn Schmiedebergs Arch Pharmacol. 2008. PMID: 18548231
Subnanomolar dopamine D3 receptor antagonism coupled to moderate D2 affinity results in favourable antipsychotic-like activity in rodent models: I. neurochemical characterisation of RG-15.
Kiss B, Laszlovszky I, Horváth A, Némethy Z, Schmidt E, Bugovics G, Fazekas K, Gyertyán I, Agai-Csongor E, Domány G, Szombathelyi Z. Kiss B, et al. Among authors: gyertyan i. Naunyn Schmiedebergs Arch Pharmacol. 2008 Nov;378(5):515-28. doi: 10.1007/s00210-008-0308-5. Epub 2008 Jun 13. Naunyn Schmiedebergs Arch Pharmacol. 2008. PMID: 18551280
Cariprazine (RGH-188), a dopamine D(3) receptor-preferring, D(3)/D(2) dopamine receptor antagonist-partial agonist antipsychotic candidate: in vitro and neurochemical profile.
Kiss B, Horváth A, Némethy Z, Schmidt E, Laszlovszky I, Bugovics G, Fazekas K, Hornok K, Orosz S, Gyertyán I, Agai-Csongor E, Domány G, Tihanyi K, Adham N, Szombathelyi Z. Kiss B, et al. Among authors: gyertyan i. J Pharmacol Exp Ther. 2010 Apr;333(1):328-40. doi: 10.1124/jpet.109.160432. Epub 2010 Jan 21. J Pharmacol Exp Ther. 2010. PMID: 20093397
Carbamoyloximes as novel non-competitive mGlu5 receptor antagonists.
Galambos J, Wágner G, Nógrádi K, Bielik A, Molnár L, Bobok A, Horváth A, Kiss B, Kolok S, Nagy J, Kurkó D, Bakk ML, Vastag M, Sághy K, Gyertyán I, Gál K, Greiner I, Szombathelyi Z, Keseru GM, Domány G. Galambos J, et al. Among authors: gyertyan i. Bioorg Med Chem Lett. 2010 Aug 1;20(15):4371-5. doi: 10.1016/j.bmcl.2010.06.075. Epub 2010 Jun 17. Bioorg Med Chem Lett. 2010. PMID: 20615697
80 results